🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Italy / NCT06920784
Recruiting Not applicable

Prismatic Adaptation in Cognitive Rehabilitation

NCT06920784 · tracked via the Priya Life Science Italy tracker
Phase
Not applicable
Started
2024-11-07
Last updated
2026-03-25

Condition(s) studied

Traumatic Brain Injury

Investigational drug(s) / intervention(s)

PRISMATIC ADAPTATIONSerious games

PRISMATIC ADAPTATION: The experimental treatment includes a session of prismatic adaptation, in which patients, wearing priasmatic lenses, performs pointing exercises using an 11'' tablet. The visual target is represented by a black squares randomly presented in one of three spatial positions of the tablet's screen (in the centre of the screen or at 21° to the right or to the left space). Taking into account the type of lesion resulting from traumatic brain injury, the prismatic deviation induced by the lenses will be changed alternately from right to left. Then patients will wear rightward prism lenses for 5 days and leftward prism lenses for other 5 days. The prismatic deviation will be randomized. Following these prismatic adaptation, lasting 10 minutes, cognitive training with serious games will be performed, for the remaining 30 minutes.

Serious games: patients receiving the same serious games for 10 days over a span of 2 weeks, withouth prismatic adaptation session.

Study summary

The study aims to evaluate the effects of prismatic adaptation and then of a novel rehabilitation protocol that combines PA and Serious Games on cognitive and behavioural deficits in patients with traumatic brain injury , compared to a rehabilitation training without prismatic adaptation.

Moreover, this study aims to assess the impact of this rehabilitation protocol on functional cognitive outcomes.

Hypothesis Hypothesis 1 (H1): It is postulated that the utilization of Prismatic Adaptation Treatment (PAT) has a positive impact on the enhancement of cognitive outcome among patients suffering from TBI

Hypothesis 2 (H2): It is hypothesized that there will be discernible alterations in resting-state Electroencephalography (EEG) patterns between the initial assessment point (T0) and the subsequent measurement during the course of treatment (T1) in individuals diagnosed with TBI

Assessment times of outcome measures will be conducted before the experimental treatment (T0) and after the 10 rehabilitation sessions (T1).

Patients will be randomized into two groups:

1. Experimental group: Patients receiving treatment with prismatic lenses and serious games lasting 10 days over a span of 2 weeks, for 40 minutes each session.
2. Control group: patients receiving the same serious games for 10 days over a span of 2 weeks, withouth prismatic adaptation session.

Both groups will receive also the standard cognitive rehabilitation for the detected deficits, using paper and pen materials.

Each rehabiliation session will last aproximately 1 hour for 5 days a week for 2 weeks.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age \>18 years * Traumatic brain injury (TBI) * Rancho Level of Cognitive Functioning (LCF) for TBI patients \> 4 * Admission within 90 days from the onset Exclusion Criteria: * Unilateral Spatial Neglect * Aphasia * Severe vigilance deficits * Severe verbal comprehension deficits * Motor deficits of both hands * Previous neurological stroke * Previous neurological disease * Previous psychiatric disease * Use of alcohol or drugs * Severe visual deficits * Premorbid dementia

Primary outcome measure(s)

Trial sites (5)

FacilityCityRegionStatus
Istituti Clinici Scientifici Maugeri IRCCS Bari Italy Recruiting
Istituti Clinici Scientifici Maugeri IRCCS Bari Italy Recruiting
Istituti Clinici Scientifici Maugeri IRCCS Pavia Italy Recruiting
Istituti Clinici Scientifici Maugeri IRCCS Sciacca Italy Recruiting
Istituti Clinici Scientifici Maugeri IRCCS Telese Terme Italy Recruiting

More Istituti Clinici Scientifici Maugeri SpA trials in Italy

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06920784 on ClinicalTrials.gov ↗ ← All trials in Italy